Phase 2 ACTIVATE trials to advance globally in metastatic patients who have progressed on available therapiesBotensilimab, alone and in combination...
Patricia Carlos named Chief Regulatory, Quality, and Safety OfficerTodd Yancey, MD named Senior Global Clinical Development, Medical Affairs and Commercial...
Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers Combining cisplatin...
Broad antitumor immune responses and demonstration of durable disease control from solid tumor patients who previously failed one or more...
- Best-in-class profile demonstrated with repeat dosing across dose levels - - Antitumor activity observed in cold tumors with steady...
Top-line findings were presented today at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive...
NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
NEEDHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing...
Montrouge, France, September 2, 2022 DBV Technologies to Present at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345...
PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model LAWRENCEVILLE, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN),...
Submission follows application for Omicron BA.1-adapted bivalent vaccine submitted in July If authorized, both Omicron BA.1-adapted and Omicron BA.4/5-adapted bivalent...
Oslo, Norway, 26 August 2022 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's first-half year...
– Investigational New Drug Application for CNTY-101, a CAR-iNK product candidate targeting CD19 for B-cell malignancies, cleared by FDA – – First...
Sepsis Phase II protocol amendments have been cleared by regulatory authorities in Israel, Spain, and Greece. In addition to these...
GARDEN CITY, N.Y. and HAMILTON, Bermuda, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air,...
Updated analysis from 34 cases occurring at least seven days following a three-dose regimen showed 73.2% vaccine efficacy among children...
Former Medicine Development Leader for MAGE-A4+ Autologous Cell Therapies Will Support Advancement of CDR-Life’s M-gager® Solid Tumor TherapiesZÜRICH, Switzerland, Aug....
— Trial met primary endpoint of overall survival and all secondary endpoints — — Selected as a late-breaker presentation — —...
Dosed first patient in Phase I/II trial evaluating Allocetra™ combined with chemotherapy in patients with peritoneal metastases arising from solid...
SAN DIEGO and BASEL, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation precision...